CN115850241A - 一种含α-酮骨架的取代杂环类化合物及其用途 - Google Patents
一种含α-酮骨架的取代杂环类化合物及其用途 Download PDFInfo
- Publication number
- CN115850241A CN115850241A CN202111118406.6A CN202111118406A CN115850241A CN 115850241 A CN115850241 A CN 115850241A CN 202111118406 A CN202111118406 A CN 202111118406A CN 115850241 A CN115850241 A CN 115850241A
- Authority
- CN
- China
- Prior art keywords
- chain
- branched
- straight
- methyl
- alkane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 32
- 208000002193 Pain Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000036407 pain Effects 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 5
- 230000036506 anxiety Effects 0.000 claims abstract description 5
- 208000035475 disorder Diseases 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 229930003827 cannabinoid Natural products 0.000 claims abstract description 4
- 239000003557 cannabinoid Substances 0.000 claims abstract description 4
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 4
- 206010003805 Autism Diseases 0.000 claims abstract description 3
- 208000020706 Autistic disease Diseases 0.000 claims abstract description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 3
- 206010041250 Social phobia Diseases 0.000 claims abstract description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 3
- 208000016620 Tourette disease Diseases 0.000 claims abstract description 3
- 208000006454 hepatitis Diseases 0.000 claims abstract description 3
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 3
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 3
- 208000014674 injury Diseases 0.000 claims abstract description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 3
- 230000008733 trauma Effects 0.000 claims abstract 2
- -1 oxyindenyl Chemical group 0.000 claims description 117
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 150000001924 cycloalkanes Chemical class 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000005997 bromomethyl group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 4
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 4
- 125000005245 nitryl group Chemical group [N+](=O)([O-])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 3
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims description 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 2
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 2
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims description 2
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 2
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 claims 2
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 claims 2
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 5
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract description 2
- 239000007787 solid Substances 0.000 description 73
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 60
- 238000006243 chemical reaction Methods 0.000 description 53
- 239000000243 solution Substances 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 29
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 28
- 238000004440 column chromatography Methods 0.000 description 26
- 238000001035 drying Methods 0.000 description 26
- 239000012074 organic phase Substances 0.000 description 22
- 238000003756 stirring Methods 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 238000005406 washing Methods 0.000 description 20
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 description 18
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 14
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000010791 quenching Methods 0.000 description 11
- 230000000171 quenching effect Effects 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000002621 endocannabinoid Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 7
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- 208000000094 Chronic Pain Diseases 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- JYUQEWCJWDGCRX-UHFFFAOYSA-N tert-butyl 4-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)CC1 JYUQEWCJWDGCRX-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000003940 fatty acid amidase inhibitor Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000001590 oxidative effect Effects 0.000 description 5
- RYSUBUJIGPJSFC-UHFFFAOYSA-N piperidin-4-yl(pyridin-2-yl)methanone Chemical class C=1C=CC=NC=1C(=O)C1CCNCC1 RYSUBUJIGPJSFC-UHFFFAOYSA-N 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 229960000836 amitriptyline Drugs 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000005605 benzo group Chemical group 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 210000003194 forelimb Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical group O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- UTJVSPKRDDKHND-UHFFFAOYSA-N 5-chloro-1-methylindole-2-carboxylic acid Chemical compound ClC1=CC=C2N(C)C(C(O)=O)=CC2=C1 UTJVSPKRDDKHND-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 3
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- HICSZYJKDHUQIT-UHFFFAOYSA-N piperidin-4-yl(1,3-thiazol-2-yl)methanone Chemical class N=1C=CSC=1C(=O)C1CCNCC1 HICSZYJKDHUQIT-UHFFFAOYSA-N 0.000 description 3
- MRDVXJDEJHXVRM-UHFFFAOYSA-N piperidin-4-yl(pyridin-4-yl)methanone Chemical class C=1C=NC=CC=1C(=O)C1CCNCC1 MRDVXJDEJHXVRM-UHFFFAOYSA-N 0.000 description 3
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229960003147 reserpine Drugs 0.000 description 3
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- OFFSPAZVIVZPHU-UHFFFAOYSA-N 1-benzofuran-2-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)=CC2=C1 OFFSPAZVIVZPHU-UHFFFAOYSA-N 0.000 description 2
- IBNGPIOSWCMJGG-UHFFFAOYSA-N 1-methylindole-2-carbaldehyde Chemical compound C1=CC=C2N(C)C(C=O)=CC2=C1 IBNGPIOSWCMJGG-UHFFFAOYSA-N 0.000 description 2
- MAHAMBLNIDMREX-UHFFFAOYSA-N 1-methylindole-2-carboxylic acid Chemical compound C1=CC=C2N(C)C(C(O)=O)=CC2=C1 MAHAMBLNIDMREX-UHFFFAOYSA-N 0.000 description 2
- PPPRLXXCIJKANA-UHFFFAOYSA-N 2-(3-chlorophenyl)-1,3,4-oxadiazole Chemical compound ClC1=CC=CC(C=2OC=NN=2)=C1 PPPRLXXCIJKANA-UHFFFAOYSA-N 0.000 description 2
- BLCGXJDZZBOCSE-UHFFFAOYSA-N 2-(furan-2-yl)-1,3,4-oxadiazole Chemical class C1=COC(C=2OC=NN=2)=C1 BLCGXJDZZBOCSE-UHFFFAOYSA-N 0.000 description 2
- ZEOMRHKTIYBETG-UHFFFAOYSA-N 2-phenyl-1,3,4-oxadiazole Chemical class O1C=NN=C1C1=CC=CC=C1 ZEOMRHKTIYBETG-UHFFFAOYSA-N 0.000 description 2
- WKTRMACWCCVROF-UHFFFAOYSA-N 2-pyridin-3-yl-1,3,4-oxadiazole Chemical class O1C=NN=C1C1=CC=CN=C1 WKTRMACWCCVROF-UHFFFAOYSA-N 0.000 description 2
- WEQPIOPUIOFSKA-UHFFFAOYSA-N 2-thiophen-2-yl-1,3,4-oxadiazole Chemical class C1=CSC(C=2OC=NN=2)=C1 WEQPIOPUIOFSKA-UHFFFAOYSA-N 0.000 description 2
- FNGKCGVPXZTHHL-UHFFFAOYSA-N 6-chloropyridine-2-carbohydrazide Chemical compound NNC(=O)C1=CC=CC(Cl)=N1 FNGKCGVPXZTHHL-UHFFFAOYSA-N 0.000 description 2
- 208000007415 Anhedonia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- FRLLPWADCHCBBY-UHFFFAOYSA-N ethyl 1-methylindole-2-carboxylate Chemical compound C1=CC=C2N(C)C(C(=O)OCC)=CC2=C1 FRLLPWADCHCBBY-UHFFFAOYSA-N 0.000 description 2
- GECRCAVZSPCTDM-UHFFFAOYSA-N ethyl 5-chloro-1-methylindole-2-carboxylate Chemical compound ClC1=CC=C2N(C)C(C(=O)OCC)=CC2=C1 GECRCAVZSPCTDM-UHFFFAOYSA-N 0.000 description 2
- 150000002193 fatty amides Chemical class 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- QNYRAEKLMNDRFY-UHFFFAOYSA-N jzl195 Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)N1CCN(CC=2C=C(OC=3C=CC=CC=3)C=CC=2)CC1 QNYRAEKLMNDRFY-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical group O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- XOKJWBRMJFHQEZ-UHFFFAOYSA-N tert-butyl 4-(1,3-oxazole-2-carbonyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C(=O)C1=NC=CO1 XOKJWBRMJFHQEZ-UHFFFAOYSA-N 0.000 description 2
- RKLBYZHXXUDLPI-UHFFFAOYSA-N tert-butyl 4-(methoxymethylcarbamoyl)piperidine-1-carboxylate Chemical compound COCNC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 RKLBYZHXXUDLPI-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- ZPGPPKNEZAGQGO-UHFFFAOYSA-N 1,3-oxazol-2-yl(piperidin-4-yl)methanone Chemical class N=1C=COC=1C(=O)C1CCNCC1 ZPGPPKNEZAGQGO-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PAJALBWYDSQWAV-UHFFFAOYSA-N 1-isocyanosulfonyl-4-methylbenzene Chemical compound CC1=CC=C(S(=O)(=O)[N+]#[C-])C=C1 PAJALBWYDSQWAV-UHFFFAOYSA-N 0.000 description 1
- XWWZTYWUMVMFNF-UHFFFAOYSA-N 3-(bromomethyl)quinoline Chemical compound C1=CC=CC2=CC(CBr)=CN=C21 XWWZTYWUMVMFNF-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- PHRDZSRVSVNQRN-UHFFFAOYSA-N 3-chlorobenzohydrazide Chemical compound NNC(=O)C1=CC=CC(Cl)=C1 PHRDZSRVSVNQRN-UHFFFAOYSA-N 0.000 description 1
- YPYPBEGIASEWKA-UHFFFAOYSA-N 5-phenyl-1,3-oxazole Chemical class O1C=NC=C1C1=CC=CC=C1 YPYPBEGIASEWKA-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- ULMHMJAEGZPQRY-UHFFFAOYSA-N N-(tert-butoxycarbonyl)piperidin-2-one Chemical compound CC(C)(C)OC(=O)N1CCCCC1=O ULMHMJAEGZPQRY-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- QQXQAEWRSVZPJM-UHFFFAOYSA-N ethyl 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OCC)=CC2=C1 QQXQAEWRSVZPJM-UHFFFAOYSA-N 0.000 description 1
- LWKIFKYHCJAIAB-UHFFFAOYSA-N ethyl 5-chloro-1h-indole-2-carboxylate Chemical compound ClC1=CC=C2NC(C(=O)OCC)=CC2=C1 LWKIFKYHCJAIAB-UHFFFAOYSA-N 0.000 description 1
- QMVJTCIUKISOGR-UHFFFAOYSA-N ethyl 6-chloro-1-methylindole-2-carboxylate Chemical compound C1=C(Cl)C=C2N(C)C(C(=O)OCC)=CC2=C1 QMVJTCIUKISOGR-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- XZBIXDPGRMLSTC-UHFFFAOYSA-N formohydrazide Chemical compound NNC=O XZBIXDPGRMLSTC-UHFFFAOYSA-N 0.000 description 1
- SKTSVWWOAIAIKI-UHFFFAOYSA-N furan-2-carbohydrazide Chemical compound NNC(=O)C1=CC=CO1 SKTSVWWOAIAIKI-UHFFFAOYSA-N 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000004914 glial activation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- TWUXBVMXSBEKHA-UHFFFAOYSA-N methyl 6-chloropyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(Cl)=N1 TWUXBVMXSBEKHA-UHFFFAOYSA-N 0.000 description 1
- QCCJUEURAZMEGY-UHFFFAOYSA-N methyl 6-methoxypyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(OC)=N1 QCCJUEURAZMEGY-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007230 neural mechanism Effects 0.000 description 1
- 229940121367 non-opioid analgesics Drugs 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- HOOIOEJUUDYIKC-UHFFFAOYSA-N tert-butyl 4-(1,3-thiazole-2-carbonyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C(=O)C1=NC=CS1 HOOIOEJUUDYIKC-UHFFFAOYSA-N 0.000 description 1
- WLTDRFFLUASWBG-UHFFFAOYSA-N tert-butyl 4-(pyridine-4-carbonyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C(=O)C1=CC=NC=C1 WLTDRFFLUASWBG-UHFFFAOYSA-N 0.000 description 1
- ZXAPIQZSJHLLDS-UHFFFAOYSA-N tert-butyl pyridine-4-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=NC=C1 ZXAPIQZSJHLLDS-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- SOGBOGBTIKMGFS-UHFFFAOYSA-N thiophene-2-carbohydrazide Chemical compound NNC(=O)C1=CC=CS1 SOGBOGBTIKMGFS-UHFFFAOYSA-N 0.000 description 1
- 238000010415 tidying Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
本发明公开了一种含α‑酮骨架的取代杂环类化合物及其用途,涉及药物化学领域,具体涉及一种含α‑酮骨架的取代杂环类化合物或其药学上可接受的盐,含有这些化合物的药用组合物以及它们的医药用途,特别是作为脂肪酰胺水解酶(FAAH)抑制剂,在制备预防或治疗与FAAH相关疾病的药物中的应用,包括炎症性疾病、类风湿性关节炎、肝炎、肝纤维化、自身免疫病、疼痛、抑郁、疼痛抑郁共病、自闭症、社交恐惧症、图雷特氏综合症、神经退行性疾病、焦虑创伤后应激(PTSD)、大麻素使用紊乱疾病、药物戒断、抗肿瘤治疗。
Description
技术领域
本发明属于药物化学领域,涉及一种含α-酮骨架的取代杂环类化合物,具体涉及一种含α-酮骨架的取代杂环类FAAH抑制剂,及其在制备预防和/或治疗与FAAH相关疾病的药物中的应用。
背景技术
慢性疼痛不是预防身体伤害或疾病的早期预警,而是神经机制失常的结果,通常持续或复发超过3~6个月。越来越多的证据表明,慢性疼痛是一种多因素疾病,会加剧潜在的焦虑和抑郁等情绪障碍,进而使药物治疗更复杂。慢性疼痛患病率高、持续时间长,不仅显著降低个人的健康状况和生活质量,还会对整个社会带来巨大的经济负担。
目前,用于治疗慢性疼痛的药物主要包括非阿片类镇痛药物如扑热息痛和非甾体抗炎药;阿片类药物如可待因、双氢可待因、芬太尼和丁丙诺啡;在阿片类药物治疗无效下,抗抑郁药物如三环类抗抑郁药和5-羟色胺和去甲肾上腺素再摄取抑制剂,抗癫痫药物如加巴喷丁和普瑞巴林表现出特殊的镇痛效应。但是非甾体抗炎药的长期使用会带来严重的胃肠道、肾脏副作用,还可能增加心血管风险;阿片类药物的使用会引起呼吸抑制、成瘾、恶心、意识混乱和免疫抑制等副作用,不适于慢性疼痛的长期药物治疗。因此,开发新型的镇痛药物具有重要的研究价值和科学意义。
内源性大麻素系统广泛分布于中枢和外周神经系统,在调节疼痛、焦虑、抑郁、心血管等多种疾病的发生发展中发挥着关键作用。其主要由内源性大麻素N-花生四烯酸乙醇胺(AEA)、N-花生四稀酸甘油(2-AG),大麻素受体(CB1,CB2),与内源性大麻素合成、降解有关的酶类组成。AEA是研究最为广泛的内源性大麻素受体(CB1,CB2)激动剂,其在体内可被脂肪酰胺水解酶(FAAH)分解为乙醇胺和AA而失活。
研究表明:内源性大麻素系统(ECS)的保护作用均是通过CB受体的激活实现的。诸多临床前研究证实基因敲除或者药物抑制剂使FAAH失活,均能使机体内源性的AEA含量升高,继而激活CB、TRPV1等受体,发挥抗炎、镇痛、抗抑郁、调节大麻素紊乱、药物戒断等多种生理作用。ECS在许多病理生理状态下上调,如炎症、神经退行性疾病、胃肠道反应、代谢和心血管疾病、疼痛和癌症,在抑制疾病进展或减少体征和症状方面发挥自我保护作用。因此,抑制内源性大麻素降解是治疗多种疾病的一种治疗手段。
在生物体内,内源性大麻素被释放到细胞外,通过细胞吸收或水解被迅速清除。脂肪酰胺水解酶(FAAH)是AEA主要的代谢水解酶,FAAH酶是调控内源性脂质分子脂肪酰胺代谢的主要酶。抑制FAAH可以提高内源性脂肪酰胺水平。研究表明,FAAH抑制剂可通过抗炎、神经保护以及改善HPA轴紊乱等多种途径发挥抗抑郁作用;同时FAAH抑制剂也能够通过激活G蛋白,抑制腺苷酸环化酶和调节Na+/K+离子通道发挥镇痛作用。同时发现内源性大麻素系统主要通过抑制胶质细胞活化和中枢敏化在慢性疼痛中发挥镇痛作用。
通过抑制FAAH活性,可以减少AEA的代谢,进而激活CB受体,发挥镇痛作用。近年来,通过抑制FAAH间接激活CB受体已成为镇痛药物的研究热点,有些FAAH抑制剂已经进入临床研究,为开发新型的安全有效的镇痛药物和其他相关疾病治疗药物提供了新的途径。
发明内容
目的:本发明提供一种具有FAAH抑制活性的含α-酮骨架的取代杂环类化合物及其用途。
技术方案:为解决上述技术问题,本发明采用的技术方案为:
在本发明的第一方面,提供了一种含α-酮骨架的取代杂环类化合物,为式I所示的化合物或其药学上可接受的盐:
其中,
Ar为无取代、单取代或多取代芳杂环;
R1表示H或芳环或芳杂环;
A为4-7元饱和或不饱和的含有1-2个杂原子N、S或O的杂环;
R2、R3分别独立的表示H或取代基。
(1)Ar为无取代、单取代或多取代芳杂环,其中芳杂环选自:呋喃、噻吩、吡咯、噁唑、异噁唑、咪唑、吡唑、噻唑、异噻唑、三氮唑、1,3,4-噁二唑、1,3,4-噻二唑、1,2,4-噁二唑、1,2,4-噻二唑、吡啶、嘧啶、哒嗪、苯并噁唑、苯并噻唑、嘌呤、喹啉、异喹啉、吲哚、吲唑、噁唑并[4,5-b]吡啶、噁唑并[5,4-b]吡啶。
在一些实施例中,芳杂环选自下述基团:
(2)R1表示H、芳环或芳杂环,其中芳环或芳杂环为无取代、单取代或多取代,芳环或芳杂环选自苯基、呋喃基、噻吩基、吡咯基、噁唑基、异噁唑基、咪唑基、吡唑基、噻唑基、异噻唑基、三氮唑基、1,3,4-噁二唑基、1,3,4-噻二唑基、1,2,4-噁二唑基、1,2,4-噻二唑基、吡啶基、嘧啶基、哒嗪基,氧茚基、吲哚基、喹啉基、异喹啉基、吲唑基、苯并噁唑基、苯并噻唑基、嘌呤基、噁唑并吡啶基;芳环或芳杂环上的取代基选自H、F、Cl、Br、I、CF3、CN、羟基、甲氧基、甲基、硝基、巯基、羧基、乙烯基、溴甲基、氰甲基、C1-C10直链或支链烷烃氧基、C1-C10直链卤代烷烃或卤代支链烷烃基、卤代环烷烃,C1-C10直链烷烃或支链烷烃、环烷烃,C1-C10直链或支链烷烃取代巯基、C1-C10直链或支链烷烃酰胺基、C1-C10直链或支链烷烃酯基。
在一些实施例中,R1中,芳环选自
在一些实施例中,L选自-CO-或-CH2-;
和/或,A为5-6元饱和或不饱和的含有1-2个杂原子N或O的杂环;
和/或,R2选自H、甲基、乙基、乙酰基、苯基、吡啶基、甲氧酰基、丙酰基、甲氧乙酰基、乙氧乙酰基;优选为H、甲基;
和/或,R3选自H、F、Cl、Br、I、CF3、CN、羟基、甲氧基、甲基、硝基、巯基、羧基、乙烯基、溴甲基、氰甲基、芳基、杂环基,C1-C10直链烷烃或支链烷烃、环烷烃,C1-C10直链或支链烷烃氧基,C1-C10直链或支链烷烃取代巯基、C1-C10直链或支链烷烃酯基;优选为H、F、Cl、Br、I。
进一步的,式I所示的化合物选自:
本发明的第二个方面,提供了式I所示的化合物的制备方法,
当R1为H,Ar为呋喃基、噻吩基、吡啶基,或稠杂环如氧茚基等时,采用第一种制备方法构建Intermediate 1:
当R1为H,Ar为含两个杂原子的单杂环如噁唑、噻唑,或稠杂环如苯并噁唑、苯并噻唑时,采用第二种制备方法构建Intermediate 1:
当R1为无取代、单取代或多取代芳环,Ar为呋喃基、1,3,4-噁二唑基等时,采用第三种制备方法构建Intermediate 1:
另一方面,一种药物组合物,其中含有治疗有效量的一种或多种所述的化合物或其药学上可接受的盐或立体异构体或其前药和药学上可接受的载体;所述药学上可接受的载体为填充剂、润滑剂、乳化剂、润湿剂、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂。
本发明的第三个方面,所述的化合物、所述的药物组合物作为FAAH抑制剂,在制备预防和/或治疗与FAAH相关疾病的药物中的应用。
进一步的,所述与FAAH相关疾病包括炎症性疾病、类风湿性关节炎、肝炎、肝纤维化、自身免疫病、疼痛、抑郁、疼痛抑郁共病、自闭症、社交恐惧症、图雷特氏综合症、神经退行性疾病、焦虑创伤后应激(PTSD)、大麻素使用紊乱疾病、药物戒断、抗肿瘤治疗。
本发明通过大量的现代药理科学研究,证实了含α-酮骨架的取代杂环类化合物对FAAH具有较好的抑制活性,并适用于与FAAH相关的疾病。
附图说明
图1为化合物抗炎活性测试(*p<0.01vs control group,#p<0.05vs LPSgroup,##p<0.01vs LPS group);
图2为糖水偏好实验研究(*p<0.01vs control group,#p<0.01vs Model group);
图3为旷场实验研究(*,P value compared to control group(*P<0.01);#,Pvalue compared to model group(#P<0.05,##P<0.01).)。
具体实施方式
为了进一步阐明本发明,下面给出一系列实施例,这些实施例完全是例证性的,它们仅用来对本发明具体描述,不应当理解为对本发明的限制。
实施例1:化合物的制备
5-氯-1-甲基-1H-吲哚-2-羧酸乙酯
将5-氯-2-吲哚甲酸乙酯(1g,4.47mmol,1eq)溶于N,N-二甲基甲酰胺中,加入氢化钠(215mg,8.94mmol,2eq),氮气保护下,80℃搅拌1小时后,加入碘甲烷(834μl,13.41mmol,3eq),TLC监测反应进程。反应结束后,加入饱和氯化铵淬灭,二氯甲烷(3×30mL)萃取,有机相用无水硫酸钠干燥,减压蒸除溶剂,经柱层析分离纯化得淡黄色固体817mg,收率77%。1HNMR(400MHz,DMSO-d6)δ7.76(d,J=2.1Hz,1H),7.64(d,J=9.0Hz,1H),7.35(dd,J=8.9,2.1Hz,1H),7.24(s,1H),4.33(q,J=7.1Hz,2H),4.02(s,3H),1.34(t,J=7.1Hz,3H)ppm.
5-氯-1-甲基-1H-吲哚-2-羧酸
将5-氯-1-甲基-1H-吲哚-2-羧酸乙酯(817mg,3.45mmol,1eq)溶于甲醇水溶液,加入氢氧化钠(552mg,13.8mmol,4eq),60℃搅拌2小时后,加入1mol/L盐酸调节pH至2,有大量固体析出,抽滤,滤饼干燥得白色固体646mg,收率90%。1H NMR(400MHz,DMSO-d6)δ13.10(s,1H),7.74(d,J=2.1Hz,1H),7.61(dt,J=9.0,0.8Hz,1H),7.34-7.31(m,1H),7.19(d,J=0.9Hz,1H)ppm.
1-甲基-1H-吲哚-2-羧酸乙酯
采用与6-氯-1-甲基-1H-吲哚-2-羧酸乙酯相同的合成方法,以吲哚-2-羧酸乙酯为原料,得淡黄色固体235mg,收率44%。1H NMR(400MHz,CDCl3)δ7.81-7.79(m,1H),7.48-7.45(m,2H),7.38-7.35(m,1H),7.30-7.29(m,1H),4.29(q,J=6.4Hz,2H),1.36(t,J=6.4Hz,3H)ppm.
1-甲基-1H-吲哚-2-羧酸
将1-甲基-1H-吲哚-2-羧酸乙酯280mg,1.38mmol,1eq)溶于甲醇水溶液,加入氢氧化钠(221mg,5.52mmol,4eq),60℃搅拌下反应2小时,TLC监测反应进程。反应结束后,加入1mol/L盐酸调节pH至2,仅少量固体析出,所以用二氯甲烷:甲醇=10:1萃取三次,合并的有机相加入无水硫酸钠干燥30分钟,抽滤,滤液减压蒸除溶剂得灰白色固体203mg,收率84%。1H NMR(400MHz,DMSO-d6)δ12.96(s,1H),7.64(dd,J=8.1,1.1Hz,1H),7.44(dd,J=8.3,1.1Hz,1H),7.24(ddd,J=8.2,6.9,1.2Hz,1H),7.09-7.04(m,2H),3.37(s,3H)ppm.
4-(2-甲苯磺酰基亚苄基)哌啶-1-甲酸叔丁酯
将N-Boc-哌啶酮(1g,5mmol,1eq)和对甲基苯磺酰肼(935mg,5mmol,1eq)溶于甲醇中,室温反应6h。反应结束后减压浓缩即可得到白色固体1.56g,收率84%。1H NMR(300MHz,DMSO-d6)δ10.29(s,1H),7.79–7.71(m,2H),7.42(d,J=8.0Hz,2H),3.41(q,J=6.3Hz,4H),2.41(s,3H),2.37(d,J=6.1Hz,2H),2.24(t,J=6.1Hz,2H),1.42(s,9H).
4-烟碱基哌啶-1-羧酸叔丁酯
将4-(2-甲苯磺酰基亚苄基)哌啶-1-甲酸叔丁酯(500mg,1.36mmol,1eq)和3-吡啶甲醛(127μl,1.36mmol,1eq)溶于无水1,4-二氧六环中,加入碳酸铯(220mg,2.04mmol,1.5eq),升至110℃搅拌3小时后,加饱和氯化铵溶液淬灭,再用二氯甲烷(3×35mL)萃取,合并的有机相加入无水硫酸钠干燥,减压蒸除溶剂,经柱层析分离纯化得淡黄色油状物190mg,收率48%。1H NMR(300MHz,DMSO-d6)δ9.19(dd,J=2.3,0.9Hz,1H),8.83(dd,J=4.8,1.7Hz,1H),8.35(dt,J=8.0,2.0Hz,1H),7.61(ddd,J=7.9,4.8,0.9Hz,1H),4.00(d,J=13.0,2H),3.69(tt,J=11.3,3.6Hz,1H),2.95(s,2H),1.82(dd,J=13.6,3.5Hz,2H),1.50-1.44(m,2H),1.43(s,9H)ppm.
4-异烟酰胺基哌啶-1-羧酸叔丁酯
将4-(2-甲苯磺酰基亚苄基)哌啶-1-甲酸叔丁酯(500mg,1.36mmol,1eq)和3-吡啶甲醛(127μl,1.36mmol,1eq)溶于无水1,4-二氧六环中,加入碳酸铯(220mg,2.04mmol,1.5eq),升至110℃搅拌3小时后,加饱和氯化铵溶液淬灭,再用二氯甲烷(3×35mL)萃取,合并的有机相加入无水硫酸钠干燥,减压蒸除溶剂,经柱层析分离纯化得淡黄色油状物388mg,收率98%。1H NMR(400MHz,DMSO-d6)δ8.83-8.81(m,2H),7.86-7.84(m,2H),3.96(d,J=13.2Hz,2H),3.63(tt,J=11.3,3.6Hz,1H),2.92(s,2H),1.79(d,J=13.2Hz,2H),1.42-1.39(m,11H)ppm.
哌啶-4-基(吡啶-4-基)甲酮
将4-异烟酰胺基哌啶-1-羧酸叔丁酯溶于HCl/EA中,室温搅拌半小时,抽滤,干燥得淡黄色固体230mg,收率82%。1H NMR(400MHz,DMSO-d6)δ7.82-7.73(m,2H),7.44-7.36(m,2H),3.17-3.14(m,4H),2.76-2.67(m,1H),2.63-2.59(m,1H),2.40-2.37(m,4H)ppm.
(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮(I-1)
将哌啶-4-基(吡啶-4-基)甲酮(200mg,0.885mmol,1.0eq)和5-氯-1-甲基-1H-吲哚-2-羧酸(185mg,0.885mmol,1.0eq)溶于N,N-二甲基甲酰胺中,加入EDCI(85mg,0.442mmol,0.5eq)、1-羟基苯并三唑(60mg,0.442mmol,0.5eq)和N-甲基吗啉(195μl,1.77mmol,1.0eq),室温搅拌0.5小时后,加入30mL水,用乙酸乙酯(3×30mL)萃取,合并的有机相加入无水硫酸钠干燥,减压蒸除溶剂,经柱层析分离纯化得白色固体112mg,收率33%。1H NMR(400MHz,DMSO-d6)δ8.84-8.83(m,2H),7.88-7.87(m,2H),7.65(d,J=2.1Hz,1H),7.56(d,J=8.8Hz,1H),7.24(dd,J=8.8,2.1Hz,1H),6.65(s,1H),4.51(s,1H),4.09-3.93(m,1H),3.84-3.78(m,1H),3.76(s,3H),3.18-2.17(m,2H),2.02-1.90(m,2H),1.61-1.51(m,2H)ppm;HRMS(ESI+):m/z[M+H]+calcd for C21H21ClN3O2,382.1317;found 382.1370.
(4-异烟酰胺基哌啶-1-基)(1-甲基-1H-吲哚-2-基)甲酮(I-2)
采用与(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮相同的合成方法,以哌啶-4-基(吡啶-4-基)甲酮和1-甲基-1H-吲哚-2-羧酸为原料,得米色固体208mg,收率68%。1H NMR(400MHz,DMSO-d6)δ8.84-8.82(m,2H),7.89-7.87(m,2H),7.61-7.59(m,1H),7.51(d,J=8.3Hz,1H),7.25(tt,J=8.0,1.1Hz,1H),7.12-7.07(m,1H),6.66(s,1H),4.46-4.10(m,2H),3.83-3.78(m,1H),3.76(s,3H),3.23-3.18(m,2H),1.90(s,2H),1.61-1.51(m,2H)ppm;13C NMR(101MHz,CDCl3)δ200.95,162.73,151.19,141.63,136.28,132.86,127.28,125.97,123.75,121.19,120.75,110.95,102.70,43.62,31.32,28.37ppm;HRMS(ESI+):m/z[M+H]+calcd for C21H21N3O2,348.1707;found 348.1757.
4-吡啶甲酸叔丁酯-1-羧酸叔丁酯
采用与4-异烟酰胺基哌啶-1-羧酸叔丁酯相同的合成方法,以4-(2-甲苯磺酰基亚苄基)哌啶-1-甲酸叔丁酯和2-吡啶甲醛为原料,得淡黄色油状物249mg,收率63%。1H NMR(300MHz,DMSO-d6)δ7.74-7.70(m,2H),7.40-7.37(m,2H),3.41-3.37(m,4H),2.38-2.33(m,4H),2.23-2.19(m,1H),1.42(s,9H).
哌啶-4-基(吡啶-2-基)甲酮
将4-吡啶甲酸叔丁酯-1-羧酸叔丁酯溶于HCl/EA中,室温搅拌半小时,抽滤,干燥得浅黄色固体172mg,收率88%。1H NMR(400MHz,DMSO-d6)δ8.77-8.75(m,1H),8.08-8.00(m,2H),7.73-7.70(m,1H),4.07(tt,J=11.4,3.7Hz,1H),3.29(dt,J=12.8,3.3Hz,2H),3.03(dtd,J=12.7,10.0,2.8Hz,2H),2.00(dd,J=14.1,3.6Hz,2H),1.87-1.76(m,2H)ppm.
(5-氯-1-甲基-1H-吲哚-2-基)(4-吡啶啉基哌啶-1-基)甲酮(I-3)
采用与(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮相同的合成方法,以为哌啶-4-基(吡啶-2-基)甲酮和5-氯-1-甲基-1H-吲哚-2-羧酸原料,得浅黄色固体53mg,收率29%。1H NMR(400MHz,DMSO-d6)δ8.77(ddd,J=4.7,1.7,1.0Hz,1H),8.06-7.96(m,2H),7.69(ddd,J=7.3,4.7,1.5Hz,1H),7.66(d,J=2.0Hz,1H),7.56(d,J=8.8Hz,1H),7.25(dd,J=8.8,2.1Hz,1H),6.65(d,J=0.8Hz,1H),4.55(s,1H),4.20-4.12(m,1H),4.03-3.93(m,1H),3.76(s,3H),3.31-3.06(m,2H),1.95(s,2H),1.63-1.53(m,2H)ppm;HRMS(ESI+):m/z[M+H]+calcd for C21H21ClN3O2,382.1317;found 382.1365.
(1-(苯并呋喃-2-羰基)哌啶-4-基)(吡啶-2-基)甲酮(I-4)
采用与(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮相同的合成方法,以苯并呋喃-2-羧酸和哌啶-4-基(吡啶-2-基)甲酮为原料,得白色固体137mg,收率46.44%。1H NMR(500MHz,Chloroform-d)δ8.64(dd,J=4.2,1.7Hz,1H),7.87(dd,J=7.8,1.3Hz,1H),7.79–7.65(m,3H),7.56(d,J=1.9Hz,1H),7.46–7.37(m,2H),7.32(ddd,J=7.3,4.2,1.3Hz,1H),3.57(dd,J=8.5,5.8Hz,2H),3.49(dd,J=8.5,5.8Hz,2H),3.32(p,J=6.2Hz,1H),2.15(ddt,J=21.6,8.6,6.0Hz,4H).
(4-吡啶啉基哌啶)(喹啉-3-基)甲酮(I-5)
采用与(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮相同的合成方法,以喹啉-3-羧酸和哌啶-4-基(吡啶-2-基)甲酮为原料,得白色固体159mg,收率52.18%。1H NMR(500MHz,Chloroform-d)δ8.84(d,J=1.6Hz,1H),8.64(dd,J=4.2,1.7Hz,1H),8.59(t,J=1.7Hz,1H),8.01(ddd,J=8.3,2.3,1.0Hz,1H),7.88(ddd,J=12.4,7.5,1.2Hz,2H),7.72(td,J=7.6,1.6Hz,1H),7.65(td,J=7.5,1.1Hz,1H),7.49(td,J=8.3,1.4Hz,1H),7.32(ddd,J=7.3,4.2,1.3Hz,1H),3.64(dd,J=8.5,5.8Hz,2H),3.59(dd,J=8.5,5.8Hz,2H),3.34(p,J=6.2Hz,1H),2.17(dt,J=8.4,6.0Hz,2H),2.08(dt,J=8.4,5.9Hz,2H).
吡啶-2-基(1-(喹啉-3-基甲基)哌啶-4-基)甲酮(I-6)
将哌啶-4-基(吡啶-2-基)甲酮(200mg,1.05mmol,1eq)溶于乙腈中,加入碳酸钾(647mg,4.21mmol,4eq)和碘化钾(388mg,2.10mmol,2eq),室温搅拌30分钟后加入3-(溴甲基)喹啉(218mg,1.58mmol,1.5eq),升温至80℃搅拌2.5小时后抽滤,滤液加水后用二氯甲烷(3×30mL)萃取,合并的有机相用10%磷酸二氢钾(3×30mL)洗涤,再用饱和食盐水(3×30mL)洗涤,最后加入无水硫酸钠干燥,减压蒸除溶剂,经柱层析分离纯化得浅黄色固体109mg,收率31%。1H NMR(300MHz,DMSO-d6)δ8.68(dd,J=4.2,1.4Hz,1H),8.59(d,J=1.6Hz,1H),8.04–7.95(m,3H),7.93–7.79(m,2H),7.85–7.75(m,1H),7.62–7.47(m,2H),7.52–7.40(m,1H),3.71(s,1H),3.22(q,J=6.1Hz,1H),3.02–2.77(m,3H),2.07–1.80(m,4H).
4-(噁唑-2-羰基)哌啶-1-甲酸叔丁酯
将噁唑(284μl,4.32mmol,1.2eq)溶于无水THF中,-40℃下缓慢加入LDA(3.6ml,7.2mmol,2eq),搅拌30min后加入1-Boc-4-[(甲氧基)甲基氨基甲酰]哌啶(1g,3.6mmol,1eq)的THF溶液,然后升至室温反应过夜。反应结束后,加入饱和氯化铵溶液淬灭,然后用EA萃取3次,合并有机相,再用饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得228mg,收率22%。1H NMR(400MHz,CDCl3)δ8.19(d,J=0.8Hz,1H),7.62(d,J=0.9Hz,1H),3.84-3.79(m,2H),3.75-3.69(m,2H),3.24-3.19(m,1H),2.14-2.04(m,4H),1.45(s,9H)ppm.
恶唑-2-基(哌啶-4-基)甲酮
将4-(噁唑-2-羰基)哌啶-1-甲酸叔丁酯溶于少量EA中,加入HCl/EA,室温反应30min,有大量白色固体析出,过滤并干燥得白色固体134mg,收率87%。1H NMR(400MHz,DMSO-d6)δ9.10(s,1H),8.74(s,1H),3.29-3.23(m,2H),3.11(s,2H),2.99-2.89(m,2H),1.85-1.72(m,4H)ppm.
(5-氯-1-甲基-1H-吲哚-2-基)(4-(恶唑-2-羰基)哌啶-1-基)甲酮(I-7)
参照(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮的合成方法,得79mg固体,收率23%。1H NMR(400MHz,DMSO-d6)δ8.44((d,J=1.7Hz,1H),7.67-7.65(m,1H),7.59-7.55(m,2H),7.27-7.23(m,1H),6.65(s,1H),4.52(s,1H),4.04-3.93(m,1H),3.76(s,3H),3.73-3.69(m,1H),3.17-3.11(m,2H),2.01-2.00(m,2H),1.66-1.56(m,2H)ppm;HRMS(ESI+):m/z[M+H]+calcd for C19H19ClN3O3,372.1109;found 372.1164.
4-(噻唑-2-羰基)哌啶-1-甲酸叔丁酯
将噻唑(312μl,4.41mmol,1.2eq)溶于无水THF中,-40℃下缓慢加入LDA(3.6ml,7.2mmol,2eq),搅拌30min后加入1-Boc-4-[(甲氧基)甲基氨基甲酰]哌啶(1g,3.67mmol,1eq)的THF溶液,然后升至室温反应过夜。反应结束后,加入饱和氯化铵溶液淬灭,然后用EA萃取3次,合并有机相,再用饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得228mg,收率22%。,得浅黄色油状物595mg,收率56%。1H NMR(400MHz,CDCl3)δ7.90(d,J=4.8Hz,1H),7.62(d,J=4.6Hz,1H),3.79-3.74(m,2H),3.48-3.43(m,2H),3.27-3.23(m,1H),2.24-2.11(m,4H),1.45(s,9H).
哌啶-4-基(噻唑-2-基)甲酮
将4-(噻唑-2-羰基)哌啶-1-甲酸叔丁酯溶于少量EA中,加入HCl/EA,室温反应30min,有大量白色固体析出,过滤并干燥得白色固体376mg,收率87%。1H NMR(400MHz,DMSO-d6)δ9.25(s,1H),8.91(s,1H),3.40(s,1H),3.28-3.22(m,2H),3.01-2.88(m,3H),1.85-1.70(m,4H)ppm.
(5-氯-1-甲基-1H-吲哚-2-基)(4-(噻唑-2-羰基)哌啶-1-基)甲酮(I-8)
参照(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮的合成方法,得237mg固体,收率47%。1H NMR(400MHz,DMSO-d6)δ8.25(d,J=3.0Hz,1H),8.19(d,J=3.0Hz,1H),7.66(d,J=2.0Hz,1H),7.56(d,J=8.8Hz,1H),7.25(dd,J=8.8,2.0Hz,1H),6.65(d,J=3.0Hz,1H),4.71–4.35(m,1H),4.21–3.96(m,1H),3.95–3.83(m,1H),3.76(s,3H),3.31–3.00(m,2H),2.16–1.90(m,2H),1.78–1.54(m,2H).
4-(苯并[d]噻唑-2-羰基)哌啶-1-甲酸叔丁酯
采用与4-(噻唑-2-羰基)哌啶-1-甲酸叔丁酯相同的合成方法,以苯并噻唑为原料,得淡黄色固体325mg,收率51%。1H NMR(300MHz,DMSO-d6)δ8.33-8.25(m,2H),7.73-7.64(m,2H),4.05(d,J=13.2Hz,2H),3.90(tt,J=11.4,3.6Hz,1H),2.97(s,2H),2.04-1.99(m,2H),1.65-1.45(m,2H),1.44(s,9H)ppm.
苯并[d]噻唑-2-基(哌啶-4-基)甲酮
将苯并[d]噻唑-2-基(哌啶-4-基)甲酮溶于少量EA中,加入HCl/EA,室温反应30min,有大量白色固体析出,过滤并干燥得白色固体256mg,收率97%。1H NMR(300MHz,DMSO-d6)δ8.33-8.23(m,2H),7.74-7.65(m,2H),4.02(tt,J=11.2,3.7Hz,1H),3.35(s,2H),3.18-3.06(m,2H),2.22-2.17(m,2H),2.01-1.87(m,2H)ppm.
苯并[d]噻唑-2-基(1-(5-氯-1-甲基-1H-吲哚-2-羰基)哌啶-4-基)甲酮(I-9)
参照(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮的合成方法,得24mg固体,收率30%。1H NMR(300MHz,DMSO-d6)δ8.32-8.27(m,2H),7.76-7.57(m,4H),7.29-7.25(m,1H),6.69(s,1H),4.59(s,1H),4.08-4.06(m,2H),3.79(s,3H),3.42-3.39(m,2H),2.15(s,2H),1.76-1.69(m,2H)ppm;HRMS(ESI+):m/z[M+H]+calcd for C23H21ClN3O2S,438.1038;found 438.1118.
5-苯恶唑
将苯甲醛(1g,9.42mmol,1eq)溶于甲醇中,加入对甲基苯磺酰异腈(2.023g,10.362mmol,1.1eq)和K2CO3(2.598g,18.8mmol,2eq),80℃下回流反应1.5h。反应结束后,减压浓缩除去甲醇,再用DCM溶解过滤掉不溶物K2CO3,滤液减压浓缩后再通过柱层析纯化得固体1.03g,收率74%。1H NMR(300MHz,DMSO-d6)δ8.44(s,1H),7.74-7.71(m,2H),7.69(s,1H),7.50-7.45(m,2H),7.40-7.34(m,1H)ppm.
4-(5-苯基恶唑-2-羰基)哌啶-1-甲酸叔丁酯
将5-苯恶唑(320mg,2.208mmol,1.2eq)溶于无水THF中,-40℃下缓慢加入LDA(1.1ml,2.208mmol,1.2eq),搅拌30min后加入1-Boc-4-[(甲氧基)甲基氨基甲酰]哌啶(500mg,1.84mmol,1eq)的THF溶液,然后升至室温反应过夜。反应结束后,加入饱和氯化铵溶液淬灭,然后用EA萃取3次,合并有机相,再用饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得固体325mg,收率37%。1H NMR(400MHz,DMSO-d6)δ8.05(s,1H),7.89–7.82(m,2H),7.59–7.51(m,2H),7.51–7.44(m,1H),4.00(d,J=13.0Hz,2H),3.59(tt,J=11.5,3.6Hz,1H),2.90(s,2H),1.92(dd,J=13.7,3.5Hz,2H),1.54–1.43(m,2H),1.43–1.39(m,9H).
(5-苯基恶唑-2-基)(哌啶-4-基)甲酮
将4-(5-苯基恶唑-2-羰基)哌啶-1-甲酸叔丁酯溶于氯化氢-二氧六环溶液,室温反应30min,有大量白色固体析出,过滤并干燥得固体152mg,收率77%。1H NMR(400MHz,DMSO-d6)δ8.08(s,1H),7.90–7.83(m,2H),7.59–7.45(m,3H),3.72(tt,J=11.3,3.6Hz,1H),3.33(d,J=12.8Hz,2H),3.05(q,J=12.3,11.9Hz,2H),2.11(dd,J=14.4,3.6Hz,2H),1.87(q,J=11.1Hz,2H).
(5-氯-1-甲基-1H-吲哚-2-基)(4-(5-苯基恶唑-2-羰基)哌啶-1-基)甲酮(I-10)
参照(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮的合成方法,得18mg固体,收率24%。1H NMR(400MHz,DMSO-d6)δ8.08(d,J=4.1Hz,1H),7.91–7.83(m,2H),7.69–7.66(m,1H),7.60–7.52(m,3H),7.52–7.49(m,2H),7.31–7.19(m,1H),6.67(s,1H),4.55(s,1H),4.05(s,1H),3.77(s,4H),3.71(s,1H),3.25–3.04(m,2H),2.15–1.92(m,2H),1.70–1.57(m,2H).
2-苯基-1,3,4-恶二唑
将苯甲酰肼(1g,7.345mmol,1eq)溶于原甲酸三甲酯中,加入对甲基苯磺酸(126mg,0.7345mmol,0.1eq),120℃下回流反应1.5h。反应结束后,直接柱层析纯化得固体1.05g,收率98%。1H NMR(400MHz,DMSO-d6)δ9.36(s,1H),7.91–7.86(m,2H),7.68–7.53(m,3H).
4-(5-苯基-1,3,4-恶二唑-2-羰基)哌啶-1-甲酸叔丁酯
将2-苯基-1,3,4-恶二唑(323mg,2.21mmol,1.2eq)溶于无水THF中,-40℃下缓慢加入n-BuLi(0.88ml,2.21mmol,1.2eq),搅拌30min后加入1-Boc-4-[(甲氧基)甲基氨基甲酰]哌啶(500mg,1.84mmol,1eq)的THF溶液,然后升至室温反应过夜。反应结束后,加入饱和氯化铵溶液淬灭,然后用EA萃取3次,合并有机相,再用饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得固体227mg,收率34%。1H NMR(300MHz,DMSO-d6)δ8.18–8.09(m,2H),7.80–7.62(m,3H),4.08–3.98(m,2H),3.64(tt,J=11.4,3.6Hz,1H),2.95(d,J=14.8Hz,2H),2.03(d,J=13.0Hz,2H),1.54(tt,J=12.1,6.1Hz,2H),1.44(s,9H).
(5-苯基-1,3,4-恶二唑-2-基)(哌啶-4-基)甲酮
将227mg4-(5-苯基-1,3,4-恶二唑-2-羰基)哌啶-1-甲酸叔丁酯溶于氯化氢-二氧六环溶液,室温反应30min,有大量白色固体析出,过滤并干燥得固体120mg,收率65%。1HNMR(400MHz,DMSO-d6)δ9.41–9.10(m,2H),8.11(dd,J=5.9,3.8Hz,1H),7.68(dtd,J=14.9,7.3,2.2Hz,2H),3.71–3.67(m,3H),3.28–3.21(m,1H),3.10(s,1H),2.93(d,J=11.9Hz,1H),2.17(dd,J=14.3,3.7Hz,1H),2.03–1.88(m,1H),1.79(td,J=12.1,11.3,5.9Hz,2H).
(5-氯-1-甲基-1H-吲哚-2-基)(4-(5-苯基-1,3,4-恶二唑-2-羰基)哌啶-1-基)甲酮(I-11)
参照(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮的合成方法,得16mg固体,收率21%。1H NMR(300MHz,DMSO-d6)δ8.14(dd,J=7.2,2.3Hz,2H),7.78–7.63(m,4H),7.59(dd,J=8.9,2.4Hz,1H),7.27(dt,J=8.8,2.5Hz,1H),6.69(s,1H),4.71–4.36(m,1H),4.28–3.98(m,1H),3.79(d,J=2.5Hz,4H),3.18-3.01(m,2H),2.28–1.99(m,2H),1.85–1.56(m,2H).
2-(吡啶-3-基)-1,3,4-恶二唑
将3-吡啶甲酰肼(1g,7.3mmol,1eq)溶于原甲酸三甲酯中,加入对甲基苯磺酸(126mg,0.73mmol,0.1eq),120℃下回流反应1.5h。反应结束后,加EA稀释,再分别用水和饱和食盐水洗涤3次,无水硫酸钠干燥,减压浓缩得白色固体915mg,收率85%。1H NMR(300MHz,DMSO-d6)δ9.47(d,J=3.0Hz,1H),9.22(d,J=2.9Hz,1H),8.84(ddd,J=5.0,3.5,1.7Hz,1H),8.43(ddt,J=7.8,3.8,1.9Hz,1H),7.68(dt,J=8.0,3.8Hz,1H)ppm.
4-(羟基(5-(吡啶-3-基)-1,3,4-恶二唑-2-基)甲基)哌啶-1-甲酸叔丁酯
将2-(吡啶-3-基)-1,3,4-恶二唑(250mg,1.7mmol,1eq)溶于无水THF中,-78℃下缓慢加入LDA(1.3ml,2.55mmol,1.5eq),搅拌30min后加入1-Boc-4-哌啶甲醛(362mg,1.7mmol,1eq)的THF溶液,然后升至室温,继续反应3h。反应结束后加入饱和氯化铵溶液淬灭,再用EA萃取3次,合并有机相,接着用饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得淡黄色固体290mg,收率47%。1H NMR(300MHz,DMSO-d6)δ9.20(dd,J=2.3,0.9Hz,1H),8.84(dd,J=4.8,1.6Hz,1H),8.40(dt,J=8.0,2.0Hz,1H),7.68(ddd,J=7.9,4.9,0.9Hz,1H),6.20(d,J=5.6Hz,1H),4.72(dd,J=7.3,5.6Hz,1H),3.99(t,J=16.7Hz,2H),2.72(s,2H),2.06(ddt,J=15.3,7.8,3.4Hz,1H),1.48(s,2H),1.41(s,9H),1.30-1.13(m,2H)ppm.
4-(5-(吡啶-3-基)-1,3,4-恶二唑-2-羰基)哌啶-1-甲酸叔丁酯
将4-(羟基(5-(吡啶-3-基)-1,3,4-恶二唑-2-基)甲基)哌啶-1-甲酸叔丁酯(270mg,0.75mmol,1eq)溶液DCM中,加入戴斯马丁氧化剂(636mg,1.5mmol,2eq),室温反应30min。反应结束后加入饱和碳酸氢钠溶液搅拌5min,随后用EA萃取3次,合并有机相,再分别用饱和碳酸氢钠和饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得淡黄色固体182mg,收率68%。1H NMR(300MHz,DMSO-d6)δ9.28(dd,J=2.3,0.9Hz,1H),8.90(dd,J=4.8,1.7Hz,1H),8.50(dt,J=8.1,1.9Hz,1H),8.06-7.96(m,1H),4.03(d,J=13.3Hz,2H),3.65(tt,J=11.4,3.7Hz,1H),2.97(s,2H),2.06-2.00(m,2H),1.65-1.48(m,2H),1.44(s,9H),1.42-1.41(m,2H)ppm.
哌啶-4-基(5-(吡啶-3-基)-1,3,4-恶二唑-2-基)甲酮
将182mg4-(5-(吡啶-3-基)-1,3,4-恶二唑-2-羰基)哌啶-1-甲酸叔丁酯溶于氯化氢-二氧六环溶液,室温反应30min,有大量白色固体析出,过滤并干燥得到白色固体111mg,收率84%。1H NMR(300MHz,DMSO-d6)δ9.33(d,J=2.3Hz,1H),8.94(dd,J=4.9,1.6Hz,1H),8.58(dt,J=8.1,2.0Hz,1H),7.79(dd,J=8.1,4.9Hz,1H),3.78(tt,J=11.2,3.7Hz,1H),3.41-3.30(m,2H),3.15-3.06(m,2H),2.21(dd,J=14.5,3.6Hz,2H),1.96(qd,J=11.6,6.0Hz,2H)ppm.
(5-氯-1-甲基-1H-吲哚-2-基)(4-(5-(吡啶-3-基)-1,3,4-恶二唑-2-羰基)哌啶-1-基)甲酮(I-12)
参照(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮的合成方法,得白色固体18mg,收率11.7%。1H NMR(400MHz,DMSO-d6)δ9.27(dd,J=2.3,0.9Hz,1H),8.88(dd,J=4.8,1.7Hz,1H),8.48(dt,J=8.1,1.9Hz,1H),7.72–7.66(m,2H),7.57(d,J=8.8Hz,1H),7.25(dd,J=8.8,2.1Hz,1H),6.67(s,1H),4.67–4.43(m,1H),4.27–3.93(m,1H),3.84–3.79(m,1H),3.77(s,3H),3.28–3.08(m,2H),2.28–1.95(m,2H),1.83–1.63(m,2H).
2-(3-氯苯基)-1,3,4-恶二唑
将3-氯苯甲酰肼(1g,7.3mmol,1eq)溶于原甲酸三甲酯中,加入对甲基苯磺酸(126mg,0.73mmol,0.1eq),120℃下回流反应1.5h。反应结束后,加EA稀释,再分别用水和饱和食盐水洗涤3次,无水硫酸钠干燥,减压浓缩得白色固体915mg,收率85%。1H NMR(300MHz,DMSO-d6)δ9.47(d,J=3.0Hz,1H),9.22(d,J=2.9Hz,1H),8.84(ddd,J=5.0,3.5,1.7Hz,1H),8.43(ddt,J=7.8,3.8,1.9Hz,1H),7.68(dt,J=8.0,3.8Hz,1H)ppm.
4-((5-(3-氯苯基)-1,3,4-恶二唑-2-基)(羟基)甲基)哌啶-1-羧酸叔丁酯
将2-(3-氯苯基)-1,3,4-恶二唑(250mg,1.7mmol,1eq)溶于无水THF中,-78℃下缓慢加入LDA(1.3ml,2.55mmol,1.5eq),搅拌30min后加入1-Boc-4-哌啶甲醛(362mg,1.7mmol,1eq)的THF溶液,然后升至室温,继续反应3h。反应结束后加入饱和氯化铵溶液淬灭,再用EA萃取3次,合并有机相,接着用饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得淡黄色固体290mg,收率47%。1H NMR(300MHz,DMSO-d6)δ9.20(dd,J=2.3,0.9Hz,1H),8.84(dd,J=4.8,1.6Hz,1H),8.40(dt,J=8.0,2.0Hz,1H),7.68(ddd,J=7.9,4.9,0.9Hz,1H),6.20(d,J=5.6Hz,1H),4.72(dd,J=7.3,5.6Hz,1H),3.99(t,J=16.7Hz,2H),2.72(s,2H),2.06(ddt,J=15.3,7.8,3.4Hz,1H),1.48(s,2H),1.41(s,9H),1.30-1.13(m,2H)ppm.
4-(5-(3-氯苯基)-1,3,4-恶二唑-2-羰基)哌啶-1-羧酸叔丁酯
将4-((5-(3-氯苯基)-1,3,4-恶二唑-2-基)(羟基)甲基)哌啶-1-羧酸叔丁酯(270mg,0.75mmol,1eq)溶液DCM中,加入戴斯马丁氧化剂(636mg,1.5mmol,2eq),室温反应30min。反应结束后加入饱和碳酸氢钠溶液搅拌5min,随后用EA萃取3次,合并有机相,再分别用饱和碳酸氢钠和饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得淡黄色固体182mg,收率68%。1H NMR(300MHz,DMSO-d6)δ9.28(dd,J=2.3,0.9Hz,1H),8.90(dd,J=4.8,1.7Hz,1H),8.50(dt,J=8.1,1.9Hz,1H),8.06-7.96(m,1H),4.03(d,J=13.3Hz,2H),3.65(tt,J=11.4,3.7Hz,1H),2.97(s,2H),2.06-2.00(m,2H),1.65-1.48(m,2H),1.44(s,9H),1.42-1.41(m,2H)ppm.
(5-(3-氯苯基)-1,3,4-恶二唑-2-基)(哌啶-4-基)甲酮
将182mg 4-(5-(3-氯苯基)-1,3,4-恶二唑-2-羰基)哌啶-1-羧酸叔丁酯溶于氯化氢-二氧六环溶液,室温反应30min,有大量白色固体析出,过滤并干燥得到白色固体111mg,收率84%。1H NMR(300MHz,DMSO-d6)δ9.33(d,J=2.3Hz,1H),8.94(dd,J=4.9,1.6Hz,1H),8.58(dt,J=8.1,2.0Hz,1H),7.79(dd,J=8.1,4.9Hz,1H),3.78(tt,J=11.2,3.7Hz,1H),3.41-3.30(m,2H),3.15-3.06(m,2H),2.21(dd,J=14.5,3.6Hz,2H),1.96(qd,J=11.6,6.0Hz,2H)ppm.
(5-氯-1-甲基-1H-吲哚-2-基)(4-(5-(3-氯苯基)-1,3,4-恶二唑-2-羰基)哌啶-1-基)甲酮(I-13)
参照(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮的合成方法,得白色固体18mg,收率11.7%。1H NMR(400MHz,DMSO-d6)δ9.27(dd,J=2.3,0.9Hz,1H),8.88(dd,J=4.8,1.7Hz,1H),8.48(dt,J=8.1,1.9Hz,1H),7.72–7.66(m,2H),7.57(d,J=8.8Hz,1H),7.25(dd,J=8.8,2.1Hz,1H),6.67(s,1H),4.67–4.43(m,1H),4.27–3.93(m,1H),3.84–3.79(m,1H),3.77(s,3H),3.28–3.08(m,2H),2.28–1.95(m,2H),1.83–1.63(m,2H).
6-氯吡啶-2-羧酸酰肼
将6-氯-2-吡啶羧酸甲酯(2g,11.66mmol,1eq)溶于甲醇中,加入水合肼(0.7g,14mmol,1.2eq),室温下搅拌20min,减压蒸馏除去溶剂甲醇,加入MTBE搅拌15min,抽滤,得到白色粉末状固体,真空干燥箱干燥,称量得白色粉末状固体1.32g,收率66%。1H NMR(300MHz,DMSO)δ9.96(s,1H),8.07(t,J=7.7Hz,1H),7.98(dd,J=7.6,1.1Hz,1H),7.73(dd,J=7.8,1.1Hz,1H),4.65(s,2H).
2-(3-氯吡啶-2-基)-1,3,4-恶二唑
将6-氯吡啶-2-羧酸酰肼(1g,5.83mmol,1eq)溶于原甲酸三甲酯中,加入对甲基苯磺酸(100mg,0.58mmol,0.1eq),120℃下回流反应1.5h。反应结束后,加EA稀释,再分别用水和饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得白色粉末状固体812mg,收率76.73%。1H NMR(300MHz,DMSO)δ9.49(s,1H),8.28–8.02(m,2H),7.82(dd,J=7.9,1.0Hz,1H).
4-(羟基(5-(3-氯吡啶-2-基)-1,3,4-恶二唑-2-基)甲基)哌啶-1-甲酸叔丁酯
将2-(3-氯吡啶-2-基)-1,3,4-恶二唑(251mg,1.38mmol,1eq)溶于无水THF中,-78℃下缓慢加入LDA(1ml,2.07mmol,1.5eq),搅拌30min后加入1-Boc-4-哌啶甲醛(295mg,1.38mmol,1eq)的THF溶液,然后升至室温,继续反应3h。反应结束后加入饱和氯化铵溶液淬灭,再用EA萃取3次,合并有机相,接着用饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得固体232.5mg,收率42.60%。1H NMR(400MHz,DMSO-d6)δ8.20(dd,J=7.7,1.0Hz,1H),8.15–8.02(m,1H),7.79(dd,J=8.0,0.9Hz,1H),6.22(d,J=5.7Hz,1H),4.71(dd,J=7.3,5.8Hz,1H),4.49–3.94(m,2H),3.24(t,J=5.8Hz,2H),2.09–1.83(m,1H),1.78–1.50(m,2H),1.38(s,9H),1.27–0.93(m,2H).
哌啶-4-基(5-(3-氯吡啶吡啶-2-基)-1,3,4-恶二唑-2-基)甲酮
将4-(羟基(5-(3-氯吡啶-2-基)-1,3,4-恶二唑-2-基)甲基)哌啶-1-甲酸叔丁酯(220mg,0.56mmol,1eq)溶液DCM中,加入戴斯马丁氧化剂(474mg,1.12mmol,2eq),室温反应30min。反应结束后加入饱和碳酸氢钠溶液搅拌5min,随后用EA萃取3次,合并有机相,再分别用饱和碳酸氢钠和饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得白色粉末状固体。将该固体溶于氯化氢-二氧六环溶液,室温反应30min,有固体析出,过滤并干燥得到淡黄色固体47.7mg,收率26.01%。1H NMR(300MHz,DMSO-d6)δ9.04(s,1H),8.84(s,1H),8.21(d,J=7.6Hz,1H),8.08(t,J=7.8Hz,1H),7.77(d,J=8.0Hz,1H),3.65(tt,J=11.5,3.8Hz,1H),3.22(s,2H),2.99(q,J=11.7Hz,2H),2.08(d,J=13.3Hz,2H),1.88–1.70(m,2H).
(5-氯-1-甲基-1H-吲哚-2-基)(4-(5-(3-氯吡啶-2-基)-1,3,4-恶二唑-2-羰基)哌啶-1-基)甲酮(I-14)
参照(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮的合成方法,得白色固体43mg,收率64.95%。1H NMR(400MHz,DMSO)δ8.31(d,J=7.7Hz,1H),8.17(t,J=7.9Hz,1H),7.86(d,J=8.0Hz,1H),7.67(d,J=2.1Hz,1H),7.57(d,J=8.8Hz,1H),7.29–7.16(m,1H),6.67(s,1H),4.47(d,J=14.7Hz,1H),3.77(s,3H),2.07(d,J=58.7Hz,2H),1.69(qd,J=12.8,12.0,4.0Hz,2H),1.33–1.16(m,4H).
2-(呋喃-2-基)-1,3,4-恶二唑
将2-呋喃甲酰肼(1.5g,11.89mmol,1eq)溶于原甲酸三甲酯中,加入对甲基苯磺酸(200mg,1.2mmol,0.1eq),120℃下回流反应1.5h。反应结束后,加EA稀释,再分别用水和饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得无色油状液体1.3g,收率80.3%。1HNMR(400MHz,DMSO)δ9.33(s,1H),8.07(s,1H),7.39(d,J=3.6Hz,1H),6.81(d,J=3.0Hz,1H).
4-(羟基(5-(呋喃-2-基)-1,3,4-恶二唑-2-基)甲基)哌啶-1-甲酸叔丁酯
将2-(呋喃-2-基)-1,3,4-恶二唑1.3g,9.55mmol,1eq)溶于无水THF中,-78℃下缓慢加入LDA(7ml,14.33mmol,1.5eq),搅拌30min后加入1-Boc-4-哌啶甲醛(2g,9.55mmol,1eq)的THF溶液,然后升至室温,继续反应3h。反应结束后加入饱和氯化铵溶液淬灭,再用EA萃取3次,合并有机相,接着用饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得黄色泡沫状固体918.8mg,收率27.53%。1H NMR(300MHz,DMSO)δ8.03(d,J=1.7Hz,1H),7.32(d,J=3.5Hz,1H),6.77(dd,J=3.5,1.8Hz,1H),6.14(d,J=5.6Hz,1H),4.64(dd,J=7.3,5.5Hz,1H),4.07–3.82(m,2H),2.75–2.44(m,2H),1.97(s,1H),1.96–1.74(m,2H),1.36(s,9H),1.20–1.10(m,2H).
4-(5-(呋喃-2-基)-1,3,4-恶二唑-2-羰基)哌啶-1-甲酸叔丁酯
将4-(羟基(5-(呋喃-2-基)-1,3,4-恶二唑-2-基)甲基)哌啶-1-甲酸叔丁酯(918mg,2.63mmol,1eq)溶液DCM中,加入戴斯马丁氧化剂(2.23g,5.26mmol,2eq),室温反应30min。反应结束后加入饱和碳酸氢钠溶液搅拌5min,随后用EA萃取3次,合并有机相,再分别用饱和碳酸氢钠和饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得白色粉末状固体663mg,收率72.62%。1H NMR(400MHz,DMSO)δ8.16(dd,J=1.8,0.8Hz,1H),7.57(dd,J=3.6,0.8Hz,1H),6.86(dd,J=3.6,1.8Hz,1H),4.01(dd,J=15.0,9.9Hz,2H),3.57(tt,J=11.3,3.6Hz,1H),2.92(s,2H),2.03–1.94(m,2H),1.59–1.43(m,2H),1.41(s,9H).
哌啶-4-基(5-(呋喃-2-基)-1,3,4-恶二唑-2-基)甲酮
将209mg4-(5-(呋喃-2-基)-1,3,4-恶二唑-2-羰基)哌啶-1-甲酸叔丁酯溶于氯化氢-二氧六环溶液,室温反应30min,有大量淡黄色固体析出,过滤并干燥得固体170mg,收率99.59%。1H NMR(400MHz,DMSO)δ9.07(d,J=71.9Hz,2H),8.17(d,J=1.7Hz,1H),7.59(dd,J=3.6,0.7Hz,1H),6.87(dd,J=3.6,1.8Hz,1H),3.71(tt,J=11.2,3.6Hz,1H),3.33(d,J=12.9Hz,2H),3.13–3.00(m,2H),2.21–2.12(m,2H),1.96–1.81(m,2H).
(5-氯-1-甲基-1H-吲哚-2-基)(4-(5-(呋喃-2-基)-1,3,4-恶二唑-2-羰基)哌啶-1-基)甲酮(I-15)
参照(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮的合成方法,得白色固体70.1mg,收率75.46%。1H NMR(400MHz,DMSO)δ8.17(d,J=1.7Hz,1H),7.67(d,J=2.1Hz,1H),7.58(s,1H),7.57(d,J=13.7Hz,1H),7.29–7.18(m,1H),6.87(dd,J=3.6,1.7Hz,1H),6.67(s,1H),3.76(s,3H),3.73(d,J=11.9Hz,1H),3.15(s,2H),2.11(s,2H),1.67(qd,J=11.6,3.9Hz,2H),1.38–1.25(m,2H).
2-(噻吩-2-基)-1,3,4-恶二唑
将2-噻吩甲酰肼(1.4g,9.85mmol,1eq)溶于原甲酸三甲酯中,加入对甲基苯磺酸(170mg,0.99mmol,0.1eq),120℃下回流反应1.5h。反应结束后,加EA稀释,再分别用水和饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得无色油状液体1.2g,收率80.08%。1H NMR(400MHz,DMSO)δ9.30(s,1H),7.96(dd,J=5.0,1.2Hz,1H),7.91–7.82(m,1H),7.30(dd,J=5.0,3.7Hz,1H).
4-(羟基(5-(噻吩-2-基)-1,3,4-恶二唑-2-基)甲基)哌啶-1-甲酸叔丁酯
将2-(噻吩-2-基)-1,3,4-恶二唑(1.2g,7.89mmol,1eq)溶于无水THF中,-78℃下缓慢加入LDA(6ml,11.84mmol,1.5eq),搅拌30min后加入1-Boc-4-哌啶甲醛(1.7g,7.89mmol,1eq)的THF溶液,然后升至室温,继续反应3h。反应结束后加入饱和氯化铵溶液淬灭,再用EA萃取3次,合并有机相,接着用饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得黄色泡沫状固体552.5mg,收率19.17%。1H NMR(400MHz,DMSO)δ7.95(dd,J=5.0,1.2Hz,1H),7.82(dd,J=3.7,1.2Hz,1H),7.29(dd,J=5.0,3.7Hz,1H),6.16(d,J=5.6Hz,1H),4.65(dd,J=7.4,5.6Hz,1H),4.06–3.90(m,2H),2.69(s,2H),2.01(ddd,J=11.8,5.6,2.3Hz,1H),1.93–1.41(m,1H),1.38(s,9H),1.18(dtt,J=20.5,12.6,6.2Hz,2H).
4-(5-(噻吩-2-基)-1,3,4-恶二唑-2-羰基)哌啶-1-甲酸叔丁酯
将4-(羟基(5-(噻吩-2-基)-1,3,4-恶二唑-2-基)甲基)哌啶-1-甲酸叔丁酯(552mg,1.51mmol,1eq)溶液DCM中,加入戴斯马丁氧化剂(1.3g,3.02mmol,2eq),室温反应30min。反应结束后加入饱和碳酸氢钠溶液搅拌5min,随后用EA萃取3次,合并有机相,再分别用饱和碳酸氢钠和饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得黄色固体496.6mg,收率90.46%1H NMR(400MHz,DMSO)δ8.07(dd,J=5.0,1.2Hz,1H),7.99(dd,J=3.8,1.2Hz,1H),7.35(dd,J=5.0,3.8Hz,1H),3.99(d,J=13.2Hz,2H),3.57(dq,J=11.3,3.9Hz,2H),3.17(s,1H),2.03–1.94(m,2H),1.50(td,J=12.4,4.2Hz,2H),1.41(s,9H).
哌啶-4-基(5-(噻吩-2-基)-1,3,4-恶二唑-2-基)甲酮
将277mg4-(5-(噻吩-2-基)-1,3,4-恶二唑-2-羰基)哌啶-1-甲酸叔丁酯溶于氯化氢-二氧六环溶液,室温反应30min,有大量淡黄色固体析出,过滤并干燥得淡黄色固体195mg,收率85.35%1H NMR(400MHz,DMSO)δ9.13(s,1H),8.94(s,1H),8.09(dd,J=5.0,1.2Hz,1H),8.00(dd,J=3.8,1.2Hz,1H),7.36(dd,J=5.0,3.8Hz,1H),3.71(tt,J=11.2,3.6Hz,1H),3.31(s,2H),3.18–2.97(m,2H),2.16(dd,J=14.2,3.6Hz,2H),2.02–1.81(m,2H).
(5-氯-1-甲基-1H-吲哚-2-基)(4-(5-(呋喃-2-基)-1,3,4-恶二唑-2-羰基)哌啶-1-基)甲酮(I-16)
参照(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮的合成方法,得淡黄色固体90mg,收率58.69%1H NMR(400MHz,DMSO)δ8.08(dd,J=5.0,1.2Hz,1H),8.00(dd,J=3.8,1.2Hz,1H),7.67(d,J=2.0Hz,1H),7.57(d,J=8.8Hz,1H),7.35(dd,J=5.0,3.7Hz,1H),7.29–7.16(m,1H),6.67(d,J=0.9Hz,1H),4.51–4.03(m,2H),3.76(s,3H),3.75–3.65(m,1H),3.14(s,1H),2.11(s,2H),1.74–1.59(m,2H).
6-甲氧基吡啶-2-羧酸酰肼
将6-甲氧基-2-吡啶羧酸甲酯(1.04g,6.22mmol,1eq)溶于甲醇中,加入水合肼(374mg,7.46mmol,1.2eq),室温下搅拌20min,减压蒸馏除去溶剂甲醇,加入MTBE搅拌15min,抽滤,得到白色粉末状固体,真空干燥箱干燥,称量得白色粉末状固体914mg,收率87.88%。1H NMR(400MHz,DMSO)δ9.75(d,J=16.0Hz,1H),7.90–7.77(m,1H),7.55(dt,J=17.7,6.8Hz,1H),6.97(q,J=9.1,8.5Hz,1H),4.57(t,J=10.4Hz,2H),4.04–3.84(m,3H).
2-(3-甲氧基吡啶-2-基)-1,3,4-恶二唑
将6-甲氧基吡啶-2-羧酸酰肼(893mg,5.34mmol,1eq)溶于原甲酸三甲酯中,加入对甲基苯磺酸(92mg,0.53mmol,0.1eq),120℃下回流反应1.5h。反应结束后,加EA稀释,再分别用水和饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得白色粉末状固体796.7mg,收率84.18%1H NMR(400MHz,DMSO)δ9.40(s,1H),7.95(dd,J=8.3,7.3Hz,1H),7.81(dd,J=7.3,0.8Hz,1H),7.09(dd,J=8.4,0.8Hz,1H),3.95(s,3H).
4-(羟基(5-(3-甲氧基吡啶-2-基)-1,3,4-恶二唑-2-基)甲基)哌啶-1-甲酸叔丁酯
将2-(3-甲氧基吡啶-2-基)-1,3,4-恶二唑251mg,1.42mmol,1eq)溶于无水THF中,-78℃下缓慢加入LDA(1.4ml,2.84mmol,2eq),搅拌30min后加入1-Boc-4-哌啶甲醛(302mg,1.42mmol,1eq)的THF溶液,然后升至室温,继续反应3h。反应结束后加入饱和氯化铵溶液淬灭,再用EA萃取3次,合并有机相,接着用饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得黄色油状液滴248.5mg,收率44.92%1H NMR(400MHz,DMSO)δ7.94(dt,J=8.6,7.0Hz,1H),7.77(d,J=7.3Hz,1H),7.09(d,J=8.3Hz,1H),6.18(d,J=5.6Hz,1H),4.74–4.62(m,1H),4.47(t,J=5.3Hz,2H),3.92(s,3H),3.24(t,J=5.7Hz,2H),1.87(d,J=13.3Hz,1H),1.66–1.57(m,2H),1.39(d,J=1.9Hz,9H),1.27–1.20(m,2H).
4-(5-(3-甲氧基吡啶-2-基)-1,3,4-恶二唑-2-羰基)哌啶-1-甲酸叔丁酯
将4-(羟基(5-(3-甲氧基吡啶-2-基)-1,3,4-恶二唑-2-基)甲基)哌啶-1-甲酸叔丁酯(220mg,0.62mmol,1eq)溶液DCM中,加入戴斯马丁氧化剂(522mg,1.24mmol,2eq),室温反应30min。反应结束后加入饱和碳酸氢钠溶液搅拌5min,随后用EA萃取3次,合并有机相,再分别用饱和碳酸氢钠和饱和食盐水洗涤3次,无水硫酸钠干燥,最后柱层析纯化得黄色油状液滴149.1mg,收率62.45%。1H NMR(400MHz,DMSO)δ7.99(dd,J=8.3,7.3Hz,1H),7.91(dd,J=7.4,0.9Hz,1H),7.15(dd,J=8.3,0.9Hz,1H),3.97(s,3H),3.61(tt,J=11.4,3.6Hz,1H),2.07–1.96(m,2H),1.83–1.78(m,2H),1.51(qd,J=12.1,4.5Hz,2H),1.40(d,J=9.5Hz,9H),1.29–1.23(m,2H).
哌啶-4-基(5-(3-甲氧基吡啶-2-基)-1,3,4-恶二唑-2-基)甲酮
将140mg4-(5-(3-甲氧基吡啶-2-基)-1,3,4-恶二唑-2-羰基)哌啶-1-甲酸叔丁酯溶于氯化氢-二氧六环溶液,室温反应30min,有大量淡黄色固体析出,过滤并干燥得黄色固体112mg,收率95.68%。1H NMR(400MHz,DMSO)δ9.59(s,1H),9.12(s,1H),8.05–7.96(m,1H),7.92(d,J=7.2Hz,1H),7.16(d,J=8.3Hz,1H),3.97(s,3H),3.38–3.20(m,2H),3.15–3.02(m,2H),2.24–2.13(m,2H),2.04–1.97(m,1H),1.91(dtd,J=15.4,11.9,4.1Hz,2H).
(5-氯-1-甲基-1H-吲哚-2-基)(4-(5-(3-甲氧基吡啶-2-基)-1,3,4-恶二唑-2-羰基)哌啶-1-基)甲酮(I-17)
参照(5-氯-1-甲基-1H-吲哚-2-基)(4-异烟酰基哌啶-1-基)甲酮的合成方法,得淡黄色固体111.8mg,收率72.75%。1H NMR(400MHz,DMSO)δ7.98(d,J=8.0Hz,1H),7.92(d,J=7.2Hz,1H),7.67(d,J=2.0Hz,1H),7.56(s,1H),7.49–7.29(m,1H),7.29–7.24(m,1H),6.65(d,J=18.0Hz,2H),3.97(s,3H),3.77(s,3H),3.28(s,2H),2.90(s,2H),2.69(s,1H),1.69(qd,J=12.0,4.2Hz,2H),1.60–1.44(m,2H).
(5-氯-1-甲基-1H-吲哚-2-基)(4-(5-(3-甲基吡啶基)-1,3,4-恶二唑-2-羰基)哌啶-1-基)甲酮(I-18)
参照I-1的合成方法,得白色粉末状固体47mg,收率36.37%。1H NMR(400MHz,DMSO)δ7.75(t,J=2.9Hz,1H),7.63(d,J=5.4Hz,1H),7.59–7.52(m,1H),7.33(dd,J=9.3,4.0Hz,1H),7.24(d,J=9.0Hz,1H),7.19(d,J=3.7Hz,1H),6.69–6.58(m,1H),4.02(s,3H),3.76(dd,J=19.6,3.8Hz,4H),2.58(d,J=0.7Hz,3H),2.36(p,J=6.4Hz,1H),1.85–1.48(m,4H).
实施例2:体外FAAH酶抑制活性测试
FAAH可在细胞内水解AEA生成乙醇胺,针对一定量的反应底物,不同的酶活性催化生成不同量的产物,通过检测产物的量可以考察酶活性的高低。本发明依据此原理进行实验设计。依据FAAH试剂盒说明书,稀释一定浓度的FAAH,加入缓冲液、荧光标记的反应底物,然后加入各浓度的化合物,设置空白对照组、JZL-195阳性对照组,反应结束后利用酶标仪进行荧光分析,最后计算其抑制率。
具体结果如表所示:
化合物名称 | IC<sub>50</sub> |
对照组:JZL-195 | 2.810nm |
I-1 | 27.92μm |
I-2 | 14.24μm |
I-3 | 13.48μm |
I-4 | 10.06μm |
I-5 | 125.0μm |
I-6 | 131.9μm |
I-7 | 77.90nm |
I-8 | 1.029μm |
I-9 | 279.1nm |
I-10 | 112.0nm |
I-11 | 16.81nm |
I-12 | 28.55nm |
1-13 | 89.67nm |
I-14 | 6.21nm |
I-15 | 3.11nm |
I-16 | 12.94nm |
I-17 | 38.12nm |
I-18 | 49.86nm |
如上表所示,本发明的化合物具有良好的FAAH抑制活性。
实施例3:
化合物I-11抗神经炎症活性测试
利用经LPS处理的BV2细胞构建神经炎症模型,通过检测炎症因子(TNF-α、IL-1β)的释放水平考察了化合物I-11是否有抑制神经炎症的作用。结果如图1和表1所示,Control组细胞中,炎症因子(TNF-α、IL-1β)的表达水平极低;经LPS处理后后,TNF-α和IL-1β表达水平均显著升高(p<0.01);经LPS处理后后,TNF-α和IL-1β表达水平均显著升高(p<0.01);
而给予化合物I-11预处理的细胞,抑制剂1可以剂量依赖性方式降低炎症因子TNF-α和IL-1β的表达。在高浓度下(20μM),能恢复炎症因子接近正常水平。该实验结果表明,化合物1能够有效抑制LPS诱导的BV2细胞炎症反应,具有较好的抗神经炎症反应,具有进一步开发的潜力。
表1化合物I-11抗炎活性测试
*p<0.01vs control group,#p<0.05vs LPS group,##p<0.01vs LPS group.
以小鼠的醋酸扭体实验为疼痛模型测试化合物I-11的镇痛活性,实验动物信息及实验操作如下。
a)实验动物
健康的ICR小鼠,清洁级,体重为20-25g。动物房符合清洁级实验室要求,温度20~22℃,湿度40%~70%,控制光照12小时/黑暗12小时昼夜交替(8:00-20:00光照时间)。小鼠饲养于塑料鼠笼中(体积280×150×180mm),每笼10只,雌雄分开饲养,自由摄食和饮水,饲料为实验鼠颗粒饲料,饮用水为城市居民饮用水经高温灭菌后使用。动物适应性饲养时间为7天。随动物的所有处理都遵循国际疼痛研究协会伦理委员会的要求。小鼠购入后饲养于动物房中。
b)实验药品及试剂
冰醋酸,生理盐水购于中国药科大学试剂库,I-11为实验室合成化合物(纯度>98%)
c)试验方法
用饱和苦味酸溶液标记小鼠,左前肢为1号,左后肢为2号,右前肢为3号,右后肢为4号,头为5号。头加左前肢为6号,头加左后肢为7号,头加右前肢为8号,头加右后肢为9号,尾为10号。动物分组,每组n=10,雌雄各半。
本实验采用小鼠扭体实验对样品的镇痛活性进行研究。称取体重为20±2g的昆明种小鼠雌雄各半,随机分4组,每组10只。其中包括样品的高、中、低剂量组和对照组。样品以高(5mg·kg-1)、中(2.5mg·kg-1)、低(1.25mg·kg-1)剂量对小鼠皮下给药,对照组给予等量生理盐水(0.9%NaCl),给药0.5小时后,每只小鼠腹腔注射0.7%冰醋酸10mL/kg,观察并记录注射冰醋酸后15分钟小鼠的扭体次数及潜伏时间,计算镇痛百分率,进行统计学处理,以T检验判断其显著性。
镇痛百分率(%)=(对照组平均扭体次数-给药组平均扭体次数)/对照组平均扭体次数
实验结果描述
根据小鼠的醋酸扭体实验,空白对照组,吗啡组、I-11组中小鼠在15分钟内小鼠发生扭体的次数进行对比,5mg·kg-1剂量的I-11对小鼠扭体的抑制率达87.1%,表明化合物I-11具有明显的镇痛活性。
化合物I-11不同浓度对小鼠扭体次数的抑制作用
化合物I-11抗抑郁活性研究
将体重(180g-200g)雄性SD大鼠随机分成6组,每组8只,分组如下:
正常组;利血平组;阳性对照组(阿米替林,6mg/kg);I-11低剂量组(3mg/kg);I-11中剂量组(6mg/kg);I-11高剂量组(12mg/kg);
其中正常组正常饲养,其与各组大鼠腹腔注射利血平(0.2mg/kg),每天一次,持续三天。利血平造模成功后,按组别给予相应的药物。连续给药两周后,依次进行糖水消耗实验,旷场实验和强迫游泳实验。
1.1糖水偏好实验
美国精神疾病协会认为抑郁的重要特征是奖赏反应性的下降,即快感缺失,糖水偏好实验是检测实验动物奖赏反应性的较好的评价指标。
结果如图2和表2所示,模型组与空白组相比较,模型组的蔗糖饮水量显著降低(p<0.01),说明模型组大鼠出现了明显的快感缺失症状,表明抑郁模型造模成功;阳性对照组(阿米替林)与模型组相比较,治疗组的蔗糖饮水量显著升高,说明阿米替林组的大鼠抑郁症状有明显的缓解。此外,与模型组比较,I-11高剂量组与模型组比较有显著性差异(p<0.01),其效果略低于阳性对照药阿米替林,表明化合物I-11具有一定的抗抑郁效果。
表-2糖水偏好实验研究
*p<0.01vs control group,#p<0.01vs Model group.
1.2旷场实验
糖水偏好实验结束后,我们对受试动物进行了旷场实验研究。实验结果如图3和表3所示,发现,与正常组相比较,模型组旷场实验大鼠中央停留时间显著增加(p<0.01);此外穿越横格数、直立次数、理毛次数均显著减少(p<0.01)。其中,I-11高剂量组在大鼠穿越横格数、直立次数和理毛次数实验中效果与阳性对照阿米替林组相当,表明I-11具有明确的抗抑郁效果。
表3旷场实验研究
*,P value compared to control group(*P<0.01);#,P value compared tomodel group(#P<0.05,##P<0.01).
1.3强迫游泳实验
强迫游泳实验结果显示,与正常组相比,模型组大鼠强迫游泳不动时间显著延长(p<0.01)。药物干预后,阿米替林组和I-11中、高剂量组均可减少利血平模型大鼠的强迫游泳不动时间(p<0.05)。其中,I-11高剂量(12mg/kg)组效果略低于与阿米替林组(6mg/kg)效果,说明化合物1具有一定的抗抑郁潜力。结果见下表4。
表4强迫游泳实验结果
*,P value compared to control group(*P<0.01);#,P value compared tomodel group(#P<0.05,##P<0.01).
以上所述仅是本发明的优选实施方式,应当指出:对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
2.根据权利要求1所述的化合物,其特征在于,Ar为无取代、单取代或多取代芳杂环,其中芳杂环选自:呋喃、噻吩、吡咯、噁唑、异噁唑、咪唑、吡唑、噻唑、异噻唑、三氮唑、1,3,4-噁二唑、1,3,4-噻二唑、1,2,4-噁二唑、1,2,4-噻二唑、吡啶、嘧啶、哒嗪、苯并噁唑、苯并噻唑、嘌呤、喹啉、异喹啉、吲哚、吲唑、噁唑并[4,5-b]吡啶、噁唑并[5,4-b]吡啶。
4.根据权利要求1所述的化合物,其特征在于,R1表示H、芳环或芳杂环,其中芳环或芳杂环为无取代、单取代或多取代,芳环或芳杂环选自苯基、呋喃基、噻吩基、吡咯基、噁唑基、异噁唑基、咪唑基、吡唑基、噻唑基、异噻唑基、三氮唑基、1,3,4-噁二唑基、1,3,4-噻二唑基、1,2,4-噁二唑基、1,2,4-噻二唑基、吡啶基、嘧啶基、哒嗪基,氧茚基、吲哚基、喹啉基、异喹啉基、吲唑基、苯并噁唑基、苯并噻唑基、嘌呤基、噁唑并吡啶基;芳环或芳杂环上的取代基选自H、F、Cl、Br、I、CF3、CN、羟基、甲氧基、甲基、硝基、巯基、羧基、乙烯基、溴甲基、氰甲基、C1-C10直链或支链烷烃氧基、C1-C10直链卤代烷烃或卤代支链烷烃基、卤代环烷烃,C1-C10直链烷烃或支链烷烃、环烷烃,C1-C10直链或支链烷烃取代巯基、C1-C10直链或支链烷烃酰胺基、C1-C10直链或支链烷烃酯基。
6.根据权利要求1所述的化合物,其特征在于,
L选自-CO-或-CH2-;
和/或,A为5-6元饱和或不饱和的含有1-2个杂原子N或O的杂环;
和/或,R2选自H、甲基、乙基、乙酰基、苯基、吡啶基、甲氧酰基、丙酰基、甲氧乙酰基、乙氧乙酰基;优选为H、甲基;
和/或,R3选自H、F、Cl、Br、I、CF3、CN、羟基、甲氧基、甲基、硝基、巯基、羧基、乙烯基、溴甲基、氰甲基、芳基、杂环基,C1-C10直链烷烃或支链烷烃、环烷烃,C1-C10直链或支链烷烃氧基,C1-C10直链或支链烷烃取代巯基、C1-C10直链或支链烷烃酯基;优选为H、F、Cl、Br、I。
9.权利要求1-8任一项所述的式I所示的化合物或其药学上可接受的盐在制备预防和/或治疗与FAAH相关疾病的药物中的应用。
10.根据权利要求9所述的应用,其特征在于,所述与FAAH相关疾病包括炎症性疾病、类风湿性关节炎、肝炎、肝纤维化、自身免疫病、疼痛、抑郁、疼痛抑郁共病、自闭症、社交恐惧症、图雷特氏综合症、神经退行性疾病、焦虑创伤后应激、大麻素使用紊乱疾病、药物戒断、肿瘤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111118406.6A CN115850241A (zh) | 2021-09-24 | 2021-09-24 | 一种含α-酮骨架的取代杂环类化合物及其用途 |
PCT/CN2022/120795 WO2023046055A1 (zh) | 2021-09-24 | 2022-09-23 | 一种含α-酮骨架的取代杂环类化合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111118406.6A CN115850241A (zh) | 2021-09-24 | 2021-09-24 | 一种含α-酮骨架的取代杂环类化合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115850241A true CN115850241A (zh) | 2023-03-28 |
Family
ID=85653071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111118406.6A Pending CN115850241A (zh) | 2021-09-24 | 2021-09-24 | 一种含α-酮骨架的取代杂环类化合物及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115850241A (zh) |
WO (1) | WO2023046055A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007140005A2 (en) * | 2006-05-26 | 2007-12-06 | Janssen Pharmaceutica N.V. | Oxazolyl piperidine modulators of fatty acid amide hydrolase |
CN110105286A (zh) * | 2019-05-21 | 2019-08-09 | 中国药科大学 | 一种含有脲素骨架的取代杂环类化合物及其制备方法和用途 |
CN110804048A (zh) * | 2019-11-08 | 2020-02-18 | 暨南大学 | 恶唑酮类化合物及其应用、faah的正电子药物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992006086A1 (en) * | 1990-10-01 | 1992-04-16 | Janssen Pharmaceutica N.V. | Novel 4-piperidinylcarbonyl derivatives |
AU2003269242A1 (en) * | 2002-10-11 | 2004-05-04 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
-
2021
- 2021-09-24 CN CN202111118406.6A patent/CN115850241A/zh active Pending
-
2022
- 2022-09-23 WO PCT/CN2022/120795 patent/WO2023046055A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007140005A2 (en) * | 2006-05-26 | 2007-12-06 | Janssen Pharmaceutica N.V. | Oxazolyl piperidine modulators of fatty acid amide hydrolase |
CN110105286A (zh) * | 2019-05-21 | 2019-08-09 | 中国药科大学 | 一种含有脲素骨架的取代杂环类化合物及其制备方法和用途 |
CN110804048A (zh) * | 2019-11-08 | 2020-02-18 | 暨南大学 | 恶唑酮类化合物及其应用、faah的正电子药物 |
Non-Patent Citations (2)
Title |
---|
DONG-SHENG ZHAO: "Pharmacophore modeling and virtual screening for the discovery of new fatty acid amide hydrolase inhibitors", ACTA PHARMACEUTICA SINICA B, vol. 1, no. 1, pages 27 - 35, XP093053639, DOI: 10.1016/j.apsb.2011.04.003 * |
ZHEN CHEN: "Synthesis and preliminary evaluation of a novel positron emission tomography (PET) ligand for imaging fatty acid amide hydrolase (FAAH)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 30, no. 21, pages 127513, XP086300516, DOI: 10.1016/j.bmcl.2020.127513 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023046055A1 (zh) | 2023-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5658664B2 (ja) | 1,2−二置換複素環式化合物 | |
US10611770B2 (en) | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | |
CN103619841B (zh) | 杂芳基化合物及其使用方法 | |
CN106008340B (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
RU2559895C2 (ru) | Азотосодержащие производные гетероарилов | |
CN103958495A (zh) | 作为gpr-119的调节剂的新型化合物 | |
US20100130737A1 (en) | Regulating Agent of GPR34 Receptor Function | |
US20110224204A1 (en) | Di-substituted phenyl compounds | |
CN112312904A (zh) | 螺环化合物 | |
CA2907502A1 (en) | Benzimidazolone derivatives as bromodomain inhibitors | |
KR20170116177A (ko) | 아미노트라이아진 유도체 및 그들을 함유하는 의약 조성물 | |
EA028046B1 (ru) | Производные бензимидазол-пролина | |
CN103459382B (zh) | 用于抑制pask的杂环化合物 | |
US11370803B2 (en) | Heteroaryl plasma kallikrein inhibitors | |
CN110143956B (zh) | 他克林-吡啶并噻吩类化合物及其制备方法与用途 | |
JP6402115B2 (ja) | 神経学的疾患および状態の処置に有用なスピロ−キナゾリノン誘導体 | |
CN111655693A (zh) | 抑制瞬时型感受器电位a1离子通道 | |
TW200524599A (en) | Substituted tricyclic heterocycles and their uses | |
CN106255690A (zh) | 光学活性pde10抑制剂 | |
EA035406B1 (ru) | Соединения пиридиния | |
TWI724753B (zh) | 醯胺基橋連雜環類化合物、及其組合物與應用 | |
CN115850241A (zh) | 一种含α-酮骨架的取代杂环类化合物及其用途 | |
CN107466294B (zh) | 吲哚衍生物 | |
JP2011520951A (ja) | 抗マラリア薬としての新規なテトラヒドロイソキノリン類 | |
JP2018087173A (ja) | 悪性脳腫瘍治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |